Breaking News Instant updates and real-time market news.

RIGL

Rigel Pharmaceuticals

$3.35

0.01 (0.30%)

14:13
04/12/18
04/12
14:13
04/12/18
14:13

Rigel Pharmaceuticals up 30% to $4.34

The PDUFA date for Rigel Pharmaceuticals' fostamatinib in ITP is April 17. It is unclear at time of writing if the move higher in the stock is related to any FDA action on fostamatinib approval.

  • 17

    Apr

RIGL Rigel Pharmaceuticals
$3.35

0.01 (0.30%)

04/03/18
JEFF
04/03/18
NO CHANGE
Target $5
JEFF
Buy
Rigel selloff on IgAN trial miss overdone, says Jefferies
Jefferies analyst Eun Yang called the fact that Rigel Pharmaceuticals' Phase 2 trial evaluating fostamatinib in IgAN failed to meet its primary endpoint "somewhat disappointing," but also said the news does not change his valuation or view on the approvability in patients with chronic or persistent immune thrombocytopenia. The analyst, who said the company is "completely optimistic" for timely approval of fostamatinib in the ITP indication by the PDUFA date of April 17, keeps a Buy rating and $5 price target on Rigel shares, calling today's selloff "overdone."
04/03/18
HCWC
04/03/18
NO CHANGE
Target $6.7
HCWC
Buy
H.C. Wainwright says Rigel's 'small setback' a buying opportunity ahead of PDUFA
H.C. Wainwright analyst Joseph Pantginis called news that Rigel Pharmaceuticals' Phase 2 study of fostamatinib in patients with IgA nephropathy did not meet its primary endpoint a "small setback" for the company and an opportunity for investors. He believes today's selling pressure is an overreaction, adding that "brighter skies may be tomorrow, almost literally," with the company's PDUFA date for fostamatinib in ITP coming on April 17. Pantginis reiterates a Buy rating on Rigel and trimmed his price target on the stock to $6.70 from $7.
04/04/18
JEFF
04/04/18
NO CHANGE
Target $5
JEFF
Buy
Rigel selloff yesterday on failed study overdone, says Jefferies
Jefferies analyst Eun Yang says that while yesterday's Phase 2 trial results in IgA nephropathy, fostamatinib's third indication, is "somewhat disappointing," it does not change her valuation or upcoming approvability in first indication immune thrombocytopenic purpura. The analyst views the selloff yesterday in shares of Rigel Pharmaceuticals as overdone. She believes the failed study has no bearing on the approval in ITP, which has an FDA action date of April 17. Yang reiterates a Buy rating on Rigel with a $5 price target.
04/09/18
JPMS
04/09/18
NO CHANGE
JPMS
Overweight
Rigel Pharmaceuticals shares can rally 80% on FDA approval, says JPMorgan
JPMorgan analyst Anupam Rama continues to see a favorable risk/reward profile on Rigel Pharmaceuticals heading into the April 17 FDA action date for Tavalisse in immune thrombocytopenia. The analyst sees a "high probability" of approval for Tavalisse and 50%-80% share upside on the news, "assuming no major surprises in the label." The approval is setting up to be a "true binary event," with potential share downside in the 65%-80% range, Rama tells investors in a research note. He keeps an Overweight rating on Rigel shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.